CAM Innodrugs(03525.HK) up 1.50%, Ascletis ASC50 psoriasis positive
NewTimeSpace News: As of 11:23 HKT on September 29, 2026, ChinaAMC Franklin FTSE Innovative Drugs ETF (03525.HK) traded at HK$10.150, up 1.50%, with turnover of HK$491,300 and volume of 48,300 units.
The ETF is managed by China Asset Management (Hong Kong) Limited and tracks the FTSE ETF Connect Innovative Drugs Index (Net Total Return), which covers innovative drug companies listed in Hong Kong and overseas; the index has 100 constituents, about 65% of which are weighted to Hong Kong-listed securities. It has a board lot of 100 units and makes no dividend distribution.
Per an announcement by Ascletis-B (01672.HK), the company's self-developed oral small-molecule IL-17A inhibitor ASC50 produced positive results in a 28-day proof-of-concept clinical study in US patients with plaque psoriasis, with a placebo-adjusted reduction of 48.9% in the Psoriasis Area and Severity Index (PASI) score, and no liver safety signal was detected during the study.
SciBrunch Therapeutics Co., Ltd. and MSD announced an exclusive global licence agreement for SPR2015, an investigational preclinical oral KRAS G12D (ON) inhibitor, under which SciBrunch will receive a US$400 million upfront payment, with the deal carrying a total potential value of up to US$2.13 billion.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
